Neurocrine's INGREZZA shows sustained efficacy at 40 mg dose
PositiveFinancial Markets

Neurocrine's recent findings on INGREZZA highlight its sustained efficacy at a 40 mg dose, marking a significant advancement in treatment options for patients. This is important as it not only reinforces the drug's effectiveness but also offers hope for improved quality of life for those affected by movement disorders.
— Curated by the World Pulse Now AI Editorial System